Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells

被引：53

作者：

Celia, Christian ^{[1
]}

Malara, Natalia ^{[2
]}

Terracciano, Rosa ^{[2
]}

Cosco, Donato ^{[1
]}

Paolino, Donatella ^{[2
]}

Fresta, Massimo ^{[1
]}

Savino, Rocco ^{[2
]}

机构：

[1] Magna Graecia Univ Catanzaro, Fac Pharm, Dept Pharmacobiol Sci, I-88100 Germaneto, CZ, Italy

[2] Magna Graecia Univ Catanzaro, Fac Med, Dept Expt & Clin Med, I-88100 Germaneto, CZ, Italy

来源：

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 2008年 / 4卷 / 02期

关键词：

Gemcitabine; Multiple myeloma; Pegylated liposomes;

D O I：

10.1016/j.nano.2008.02.003

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

Gemcitabine-loaded pegylated unilamellar liposomes (200 nm) were proposed for the treatment of multiple myeloma cancer disease. Physicochemical and technological parameters of liposomes were evaluated by using laser light scattering and gel permeation chromatography. The growth-inhibitory activity of gemcitabine-loaded liposomes compared to the free drug was assayed in vitro on U266 (autocrine, interleukin-6-independent) and INA-6 (IL-6-dependent) multiple myeloma cell lines. Liposomes noticeably improved the growth-inhibitory activity of gemcitabine in terms of both dose-dependent and incubation-time effects. Liposomal delivery of gemcitabine consistently and significantly increased induction of apoptosis and caused a complete inhibition of proliferation. Liposomes were able to interact with multiple myeloma cells as demonstrated by confocal laser scanning microscopy and hence to improve the intracellular gemcitabine delivery. Gemcitabine-loaded liposomes were much more effective in vitro than the free drug. This formulation may offer even more in vivo advantages both in terms of drug pharmacokinetic and biodistribution. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：155 / 166

页数：12

共 60 条

[1] An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes [J].

Abraham, SA ;

Edwards, K ;

Karlsson, G ;

Hudon, N ;

Mayer, LD ;

Bally, MB .

JOURNAL OF CONTROLLED RELEASE, 2004, 96 (03) :449-461

[2] Targeting to macrophages:: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages [J].

Ahsan, FL ;

Rivas, IP ;

Khan, MA ;

Suárez, AIT .

JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) :29-40

[3]

ALEXANIAN R, 1983, BLOOD, V62, P572

[4]

ALEXANIAN R, 1992, BLOOD, V80, P887

[5] Targeted therapy for multiple myeloma [J].

Anderson, KC .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :286-294

[6] SINGLE-STEP PURIFICATION AND STRUCTURAL CHARACTERIZATION OF HUMAN INTERLEUKIN-6 PRODUCED IN ESCHERICHIA-COLI FROM A T7 RNA-POLYMERASE EXPRESSION VECTOR [J].

ARCONE, R ;

PUCCI, P ;

ZAPPACOSTA, F ;

FONTAINE, V ;

MALORNI, A ;

MARINO, G ;

CILIBERTO, G .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 198 (03) :541-547

[7] Gemcitabine-induced severe pulmonary toxicity [J].

Barlési, F ;

Villani, P ;

Doddoli, C ;

Gimenez, C ;

Kleisbauer, JP .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (01) :85-91

[8] Combined effect of surface electrostatic charge and poly(ethyl glycol) on the association of liposomes with colon carcinoma cells [J].

Borowik, T ;

Widerak, K ;

Ugorski, M ;

Langer, M .

JOURNAL OF LIPOSOME RESEARCH, 2005, 15 (3-4) :199-213

[9]

Boulikas T, 2004, ONCOL REP, V12, P3

[10]

Calvagno Maria Grazia, 2007, Current Drug Delivery, V4, P89

← 1 2 3 4 5 6 →